About CHS-0214<\/b><\/p> \n
CHS-0214 is a proposed biosimilar of etanercept (Enbrel®). This product was evaluated in a Phase 1 single dose cross-over study in healthy volunteers. In this trial, CHS-0214 met the primary bioequivalence endpoint of clinical PK similarity to Enbrel®, demonstrating a 98% geometric mean between CHS-0214 and Enbrel®. No clinically meaningful differences in other safety parameters were observed during this study. <\/p> \n
About Coherus BioSciences, Inc.<\/b><\/p> \n
Coherus is a late-stage clinical biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area<\/span> and composed of a team of industry veterans with decades of experience in pioneering biologics companies, Coherus has developed an innovative business model that leverages a strategically aligned consortium of key service providers specifically crafted to address the biosimilar opportunity and to achieve competitive scale. Coherus' commercialization partnerships include global pharmaceutical companies in Europe<\/span>, Asia<\/span> and Latin America<\/span>. <\/p> \n Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com<\/a>.<\/p> \n About Baxter International, Inc.<\/b><\/p> \n Baxter International, Inc., through its subsidiaries, develops, manufactures, and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter<\/span> applies a unique combination of expertise in medical devices, pharmaceuticals, and biotechnology to create products that advance patient care worldwide. By mid-2015, Baxter<\/span> expects to establish the BioScience businesses as a separate, publicly traded, innovation oriented biotechnology firm.<\/p> \n The exclusive collaboration between Baxter<\/span> and Coherus includes development and commercialization for the etanercept biosimilar in Europe<\/span>, Canada<\/span>, Brazil<\/span> and certain other markets.<\/p> \n This release includes forward-looking statements by Baxter International Inc. related to a clinical trial being conducted by its partner, Coherus BioSciences. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; clinical results; changes in laws and regulations; product quality or supply or patient safety issues; and other risks identified in Baxter's<\/span> most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's<\/span> website. Baxter<\/span> does not undertake to update its forward-looking statements.<\/i><\/p> \n Coherus BioSciences Contact
<\/b>Beth Jimison<\/span>
650-649-3526
BJimison@Coherus.com<\/a><\/p> \n